Continuing Single-Agent Bevacizumab as Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer

SECTION EDITOR'S NOTE: Metastatic colorectal cancer is the second leading cause of cancer death in the United States. Since 1995, treatment regimens have included capecitabine, irinotecan, oxaliplatin, bevacizumab, cetuximab, panitumumab, aflibercept, and reforafenib. These medications have dou...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Díaz-Rubio, Eduardo, Pietrantonio, Filippo, de Braud, Filippo
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2012
Soggetti:
Challenging Cases
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3500363/
https://ncbi.nlm.nih.gov/pubmed/23073991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0075
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi